New Study funded by Medicine for Malaria Venture (MMV), Switzerland, on CYP2D6 Phenotyping in Vivax Malaria Relapsers and Non-Relapsers began in April 2014 to correspond the study Radical Cure in Vivax Malaria on Indonesia Soldiers at Batallion 408H Sragen, Central Java. ALERTAsia acting as the sponsor on this study with investigators from collaborating institutes, i.e. the Faculty of Medicine, University of Indonesia, Eijkman Institute for Molecular Biology, and the Indonesian Army where its soldiers at Batallion 408H were the study subjects.
 
The primary objective of the study was to examine the frequency of fast-intermediate-slow CYP2D6 metabolism of a single does dextromethorphan among patients who relapsed after directly observed primaquine therapy compared to those who did not relapse. 26 subjects experienced relapse of vivax malaria during the course of the radical cure study. Randomly selected non-relapsing subjects were invited to join this study. The study was conducted from April 2014 to July 2014. The result has yet to be released.